Detecting Crack and Other Cocaine Use With FastPatches

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,174,009.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
2R44DA013542-02A2
Award Id:
71430
Agency Tracking Number:
DA013542
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SOCIAL SCIENCES INNOVATIONS CORP, 71 W 23RD ST, 8TH FL, NEW YORK, NY, 10010
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
HILARYLIBERTY
(917) 438-0894
LIBERTY@NDRI.ORG
Business Contact:
LISABERNHARD
(212) 845-4444
BERNHARD@NDRI.ORG
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): PharmChem Inc. has developed a new sweat patch product, the FastPatch TM, which reduces minimum wear times to detect cocaine and most other drugs of abuse from the full day typically required with standard sweat patches (Liberty et al., 1999a) to 20 or 30 minutes through mild heating (Liberty, 2003). Additionally, there is an increasing need and growing market for the detection of crack use distinct from other cocaine. Recent research (Martin et al., 1989) has identified unique pyrolytic metabolites of crack, anhydroecgo-nine methylester (AEME) and ecgonidine (ECD) through GC/MS. It is likely that a low-cost EIA procedure for detection of crack use will be available within a year, increasing the market potential for detection using a Fastpatch (tm). During Phase I, 180 subjects wore two FastPatch prototypes (one on each hand) and only one patch per subject was needed to obtain sufficient sweat eluate for GC/MS. This finding has positive market potential. Cocaine use was detected in sweat of 92.4 percent of subjects, comparable to 91 percent with EMIT urinalysis in a high prevalence sample. Crack metabolites were successfully detected in 54 percent of subjects. While there were no significant differences in detection rates between 15, 20, and 30 min. wear periods, all wear periods successfully detected substantial cocaine/crack use, and a shorter 10 min. condition will be tested. This finding has positive market potential. During Phase II, these changes will occur: Fast patches will be worn in moderate and low prevalence samples, a shorter wear period will be added, more biological tests will be included (e.g., standard sweat patches and GC/MS of urine), testing for more drugs (heroin and marijuana), data collection will expand to include both a residential drug treatment program and a workplace, low-prevalence sample, the latter a venue with positive market potential. The FastPatch avoids problems with urinalysis such as violations of privacy, dilution or substitution of specimens, possibility of disease transmission, and transport of noxious fluids. Advantages over the standard sweat patch include a longer window of detection (2-3 wks. versus 2-3 days) and a shorter minimum period of wear needed to detect most drugs (10-20 m n. versus 24 hrs.).

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government